News Analysis India

Tag: intranasal vaccine

  • India’s first intranasal Covid vaccine to be launched on Jan 26

    By PTI

    BHOPAL: Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company’s chairman and managing director Krishna Ella said here on Saturday.

    Interacting with students at the India International Science Festival in Bhopal, Ella also said that the homegrown vaccine for the lumpy skin disease in cattle, Lumpi-ProVacInd, is likely to be launched next month.

    “Our nasal vaccine will be officially launched on January 26, on Republic Day,” Ella said, participating in the ‘Face-to-Face with New Frontiers in Science’ segment of the IISF, organised at the Maulana Azad National Institute of Technology (MANIT).

    In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 per shot for private vaccination centres.

    BHOPAL: Homegrown vaccine maker Bharat Biotech will launch its intranasal COVID-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company’s chairman and managing director Krishna Ella said here on Saturday.

    Interacting with students at the India International Science Festival in Bhopal, Ella also said that the homegrown vaccine for the lumpy skin disease in cattle, Lumpi-ProVacInd, is likely to be launched next month.

    “Our nasal vaccine will be officially launched on January 26, on Republic Day,” Ella said, participating in the ‘Face-to-Face with New Frontiers in Science’ segment of the IISF, organised at the Maulana Azad National Institute of Technology (MANIT).

    In December, Bharat Biotech had announced that it would sell the intranasal vaccine for Rs 325 per shot for procurement by the government and Rs 800 per shot for private vaccination centres.

  • Intranasal Covid vaccine trials to likely end soon

    By Express News Service

    NEW DELHI: After receiving go-ahead for Covaxin for the two-years plus population by the drug regulator’s expert panel, Bharat Biotech is now preparing to submit data for its intranasal vaccine against Covid19, which has been projected as a game changer.

    The Hyderabad headquartered firm’s BBV154, on adenovirus-based platform, is set to follow a single dose regimen and the company has said that it stimulates broad immune responses at the site of infection in the nasal mucosa which is essential for blocking both infection and transmission of the SARS-CoV-2 virus. Sources said as part of the trial involving 600 participants, results of which are likely to be submitted to the Central Drugs Standard Control Organisation in the coming weeks, three dosing regimens have been adopted.

    The first group of volunteers will receive Covaxin as the first dose and the newly-developed intranasal vaccine as the second dose. The second group will get both doses of intranasal vaccine while the third group will receive only Covaxin for both doses.

    Meanwhile, authorities have said that the intranasal vaccine requires minimal training to administer and will not need syringes – meaning easier logistical support. Bharat Biotech and Washington University School of Medicine had announced a licensing agreement in September last year for the nasal vaccine candidate, under which the company had also bagged the distribution rights in markets except the US, Japan and Europe.

  • Expert panel recommends permission for phase 1 trial of Bharat Biotech’s nasal vaccine

    By PTI
    NEW DELHI: An expert panel of India’s drug regulator CDSCO on Tuesday recommended granting permission for conducting a phase 1 clinical trial of an intranasal vaccine against COVID-19 developed by Bharat Biotech, official sources said.

    A top government official said that if this vaccine works it can be a game-changer in the fight against COVID-19.

    Bharat Biotech applied to the Drugs Controller General of India (DCGI) seeking permission for conducting phase 1 and phase 2 clinical trials of the intranasal vaccine following which the subject expert committee of the CDSCO on Tuesday deliberated on the application and recommended granting permission for phase 1 trial.

    “Based on the safety and immunogenicity data of phase 1 clinical trial, the company would be given permission for conducting phase 2 clinical trial,” an official said on the condition of anonymity.

    Earlier in the day, in response to a query on whether a nasal vaccine would be effective against the disease, NITI Aayog member (health) V K Paul at a press conference said, “A nasal vaccine candidate has been identified. It has come for consideration to the drug regulator for phase 1 and phase 2 clinical trials.”

    “It looks like an exciting development because potentially, yes, this route can be used to deliver the safe antigen against which an immunological response would happen. If it does work it can be a game-changer because it is so easy to use and we look forward to this development. Such a possibility is very plausible scientifically,” Paul said.

    ALSO READ | Highly deplorable to overreact, entice fear without due diligence on COVID-19 vaccine: Vardhan

    The nasal vaccine is different from the intramuscular vaccine which recently was approved by the Indian drug regulator for restricted emergency use approval under clinical trial mode.

    Krishna Ella, the chairman of Bharat Biotech, had earlier said the company is focusing on the intranasal vaccine as existing vaccines require two-dose intramuscular injections and a country like India needs 2.6 billion syringes and needles which may add to pollution.

    An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc significantly impacting the overall cost of a vaccination drive, he had said.

    “One drop of vaccine in each of the nostrils is sufficient,” he had said.

    BBV154 (intranasal COVID-19 vaccine) preclinical testing has been completed for toxicology, immunogenicity and challenge studies.

    These studies have been conducted in the USA and India.

    Phase I human clinical trials will commence during Feb-March 2021,” an e-mail reply from the vaccine maker told PTI.